A recent Phase I clinical trial study of a tau stabilizer TPI 287 in mild-to-moderate AD, progressive supranuclear palsy (PSP), and corticobasal syndrome (CBS) patients, conveyed encouraging results with beneficial effects of TP1 287 on cognitive performance and/or nerve cells activity (based on CTAD 2017 conference news). This evidence concerns the gene MAPT and Alzheimer disease.